Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVersys AGXSWX:BIOV 4 EV-to-OCF is -4.29 as of Aug. 15, 2026. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100. Among 1,410 Biotechnology companies, BioVersys AG ranks better than 55.46% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioVersys AG's Enterprise Value is CHF94.20 Mil.
BioVersys AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-21.95 Mil. Therefore, BioVersys AG's EV-to-OCF for today is -4.29.
The historical rank and industry rank for BioVersys AG's EV-to-OCF or its related term are showing as below:
XSWX:BIOV'
s EV-to-OCF Range Over the Past 10 Years
Min: -4.56 Med: 0 Max: -4.56
Current: -4.56
During the past 2 years, the highest EV-to-OCF of BioVersys AG was -4.56. The lowest was -4.56. And the median was .
XSWX:BIOV's EV-to-OCF is ranked better than 55.46% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs XSWX:BIOV: -4.56
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioVersys AG's PE Ratio (TTM) for today is calculated as:
BioVersys AG's share price for today is CHF26.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioVersys AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-3.890.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioVersys AG EV-to-OCF Related Terms
BioVersys AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioVersys AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG EV-to-OCF Chart
BioVersys AG Annual Data
Trend
Dec24
Dec25
EV-to-OCF
0.00
-3.73
BioVersys AG Semi-Annual Data
Jun24
Dec24
Jun25
Dec25
EV-to-OCF
0.00
0.00
0.00
0.00
XSWX:BIOV vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, BioVersys AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVersys AG EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVersys AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioVersys AG's EV-to-OCF falls into.
BioVersys AG's current Enterprise Value is CHF94.20 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioVersys AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-21.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioVersys AG (XSWX:BIOV) has a EV-to-OCF of -4.29 as of Aug. 15, 2026. According to the industry distribution chart, BioVersys AG ranks #628 out of 1410 companies in the Biotechnology industry, placing it in the top 44.5%.
Is BioVersys AG's EV-to-OCF too high?
BioVersys AG's current EV-to-OCF is -4.29. Based on the distribution chart, BioVersys AG ranks #628 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioVersys AG ranks #628 out of 1410 companies for EV-to-OCF. This puts BioVersys AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. BioVersys AG's current EV-to-OCF is -4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current EV-to-OCF of -4.29. The current EV-to-OCF is -4.29. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current EV-to-OCF is -4.29 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score
Get the complete analysis for XSWX:BIOV
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIOV has been successfully added to your 
